Regorafenibisanorallybioavailablemultikinaseinhibitor.Thiscompoundisclinicallyusedinthetreatmentofmetastaticcolorectalcancerandnon-responsivegastrointestinalstromaltumors.Regorafenibdisplaysanticancerchemotherapeuticandanti-angiogenicproperties,selectiveprimarilyforVEGFR2butalsodisplayinginhibitoryactivityagainstTIE2,VEGFR1/3,PDGFR-β,FGFR1,c-Kit,RET,andB-Raf.
| CasNo. | 1019206-88-2 |
|---|---|
| Purity | ≥99% |
| Formula | C21H15ClF4N4O3•H2O |
| FormulaWt. | 500.83 |
| IUPACName | 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide;hydrate |
| Synonym | BAY73-4506 |
| Solubility | InDMSO |
| Appearance | off-whitepowder |
| StoreTemp | -20°C |
|---|---|
| ShipTemp | Ambient |
| InfoSheet | R1626InfoSheetPDF |
|---|---|
| Brochures | Ras-Raf-MEK-ERKPathwayBooklet |
Abou-ElkacemL,ArnsS,BrixG,etal.Regorafenibinhibitsgrowth,angiogenesis,andmetastasisinahighlyaggressive,orthotopiccoloncancermodel.MolCancerTher.2013Jul;12(7):1322-31.PMID:23619301.
WilhelmSM,DumasJ,AdnaneL,etal.Regorafenib(BAY73-4506):aneworalmultikinaseinhibitorofangiogenic,stromalandoncogenicreceptortyrosinekinaseswithpotentpreclinicalantitumoractivity.IntJCancer.2011Jul1;129(1):245-55.PMID:21170960.
